Mini-review Stem cell transplantation (SCT) for Waldenstrom s macroglobulinemia (WM)
|
|
- Amos Palmer
- 6 years ago
- Views:
Transcription
1 (2002) 29, Nature Publishing Group All rights reserved /02 $ Mini-review Stem cell transplantation (SCT) for Waldenstrom s macroglobulinemia (WM) Department of Blood and Marrow Transplantation at the University of Texas MD Anderson Cancer Center, Houston, TX, USA Summary: Waldenstrom s macroglobulinemia (WM) is a lowgrade lymphoplasmacytoid malignancy of unknown etiology. It primarily affects elderly patients and is characterized by a monoclonal IgM component, varying degrees of cytopenias, lymphadenopathy and manifestations related to hyperviscosity syndromes. WM is usually treated with single agent nucleoside analogues or alkylating agents that often provide high response rates and durable remissions. Recurrence of the disease after primary therapy is not uncommon, and resistance to both alkylating agents and nucleoside analogs eventually emerges. Small numbers of patients have undergone high-dose chemotherapy (HDC) with either autologous (n = 24) or allogeneic (n = 6) stem cell transplantation (SCT) as treatment for this disease. Most patients in both groups achieved remission. Results are promising and a more in-depth analysis of possible applications of this treatment modality is attempted with this minireview. (2002) 29, DOI: /sj/bmt/ Keywords: Waldenstrom s macroglobulinemia; stem cell transplantation; high-dose chemotherapy Waldenstrom s macroglobulinemia (WM) is a rare lowgrade lymphoplasmacytoid malignancy, characterized by the presence of an IgM paraprotein. WM typically affects elderly individuals, with a median age at presentation of 65 years. The disease usually has a long natural history and the patients often survive more than 5 years after the initial diagnosis. 1 Patients with WM may present with hyperviscosity syndrome, cryoglobulinemia, cold agglutinin disease, peripheral neuropathy, amyloidosis as well as lymphadenopathy and symptoms related to the cytopenias. Adverse prognostic factors in patients with WM have been analyzed in several studies and include low albumin level, increased Correspondence: Dr S Giralt, Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA age, cytopenias, the presence of cryoglobulinemia and elevated serum beta 2 microglobulin. 2 5 Treatment is generally employed when patients become symptomatic. 1 Alkylating agents, such as chlorambucil and cyclophosphamide, with or without corticosteroids, together with plasmapheresis have been the mainstay of therapy to reduce tumor burden as well as the symptoms related to hyperviscosity. More recently, the nucleoside analogues fludarabine and cladribine have been used either as single agents or in combination as frontline therapy for the disease. 1 Interferon-, anti-cd20 monoclonal antibodies as well as thalidomide have also shown activity in relapsed patients. 6 8 Patients with WM generally respond to initial therapy with either alkylating agents or nucleoside analogs. Response to treatment is considered complete when the serum monoclonal protein disappears as assessed by immunofixation and there is complete resolution of lymphadenopathy and splenomegaly with less than 20% lymphocytes in the bone marrow. Complete remissions are rare and all responding patients will eventually relapse. Reinduction of remission is possible, but eventually resistance to both alkylating agents as well as nucleoside analogs develops. Thus for practical purposes WM remains an incurable disease. High-dose chemotherapy (HDC) followed by stem cell transplantation (SCT) has been used in refractory or highrisk patients Patients with disease resistant to conventional chemotherapy have achieved durable responses after HDC followed by autologous or even allogeneic SCT. In this review we summarize the published experience with SCT in WM patients, and provide guidelines with regard to the current and possible future role of this therapeutic modality in the treatment of WM. Autologous stem cell transplantation for Waldenstrom s macroglobulinemia Twenty-four patients with WM have undergone HDC and autologous SCT and have been reported in the literature and are summarized in Table ,15 Median age was 51 (range 30 71). Fourteen patients were transplanted in a refractory or relapsed status of their disease and the remaining 10 were transplanted at a time when the disease was chemosensitive. Most patients were treated within the first
2 944 Table 1 Characteristics of 24 patients with WM who underwent HDC supported by autologous SCT Ref. Patient Age median Time to Disease status Preparative regimen Response FU in months Outcome No. (range) transplant (range) (years) (45 69) 4 (3 9) Multiple relapse untreated 3 MEL 200 (2 patients) 2 PR 15+, 9 1 AW, 1 progressed, died Mel 140+TBI (1 patient) 1PR 6 progressed died 1st remission 2 MEL 200 2PR 12+, 5+ 2AW Progressive disease 1 MEL CR 52+ 1AW (39 61) 1 year 1st remission 3 CY TBI PR 1, CR (3 30) 7 AW 1ry refractory 4 CY TBI PR Unknown Unknown 1st remission MEL 200 PR 1,CR 4 Unknown Unknown Unknown Refractory Bu MEL120 CR AW Refractory MEL 140 CR AW (30 58) 0.9 1ry refractory Thiotepa Bu CY PR AW 0.8 Refractory relapse Thiotepa Bu CY NA 1 1 early death 10 VP-16 CY TBI PR ry AML, died 1 CY TBI PR AW MEL = melphalan; CY = cyclophosphamide; TBI = total body irradiation; Bu = busulfan; VP-16 = etoposide; PR = partial remission; CR = complete remission; ED = early death; AW = alive and well; 1ry = primary; 2ry = secondary. year of initial diagnosis. The preparative regimens consisted primarily of high-dose melphalan or TBI in combination with an alkylating agent. Twenty-three of the 24 reported patients were reported to have achieved remission and only one treatment-related death was noted. The median follow-up of the surviving patients was 15 months but at least two patients were reported as alive 4.5 and 12 years post transplant without disease recurrence (Table 1). (GVHD), while two patients were reported to be alive in remission for an extended period of time after transplant (Table 2). There is also anecdotal experience from Seattle with three WM patients receiving low-dose TBI as preparative regimen who responded to treatment; however, followup is still short (personal communication with Dr David Maloney). Allogeneic stem cell transplantation for Waldenstrom s macroglobulinemia Six patients with WM who underwent an allogeneic SCT have been reported in the literature and are summarized in Table 2. 11,14,16 The median age of these patients was 45 (range 30 62) years. All patients were heavily pretreated due to refractory or relapsed disease. The median time from diagnosis to transplant was 3.1 years (range 1.3 7). Four subjects received a full myeloablative regimen, three with a TBI-containing approach and one using thiotepa, busulfan and cyclophosphamide. Two patients received a reduced intensity or non-myeloablative regimen consisting of fludarabine with cyclophosphamide or melphalan. Two patients died from complications of graft-versus-host disease Discussion It is obvious that there is only limited experience with HDC and SCT in WM, therefore, the role of this procedure in the therapy of this disease is unknown. The only conclusion that can be derived from the published data is that the procedure is feasible in some patients, that autologous transplant seems to be generally safe and well tolerated, and that both autografts and allografts can be associated with longterm remissions even in patients whose disease is refractory to alkylating agents and nucleoside analogs. Thus although feasible, HDC and SCT should be considered investigational and limited to clinical trials. There are several questions that should be addressed in the course of clinical investigation: Table 2 Six patients with WM who underwent HDC supported by allogeneic SCT Ref. Patients Age Time to Disease status Regimen Best response Follow-up Adverse events transplant (months) (years) Thiotepa Bu CY, NE 1 Early death Refractory relapse TLI CY VP16 TBI PR 6 Died of GVHD FAMP CY NR 36 Graft failure, died of disease Sensitive relapse Chlorambucil CY TBI PR 112+ None, AW Refractory relapse CY TBI CR 34+ None, AW Refractory relapse FAMP MEL140 PR 5+ None, AW Bu = busulfan; Cy = cyclophosphamide; TLI = total lymphoid irradiation; FAMP = fludarabine; ED = early death; GVHD = graft-versus-host disease.
3 (1) Should high-dose chemotherapy and stem cell transplantation be explored as frontline therapy for Waldenstrom s Macroglobulinemia? WM typically affects elderly individuals. It is estimated that around 20% of the patients will die of unrelated causes. 3 Up to 90% of patients respond to first line single agent treatment (chlorambucil or nucleoside analogue) and nearly half of patients respond to single agent salvage treatment. 4,17 21 Median survival after diagnosis has been estimated to be more than 5 years. 1 However, there are several prognostic models that have identified groups of patients who have limited survival. 2 5 In the largest report to date, Morel et al 22 were able to identify age, cytopenias and albumin as important prognostic factors, and validated these factors in an independent population. Patients with low risk disease (ie less than 65 years of age, no cytopenias, and normal albumin) had an expected survival rate at 5 years of 92% vs 27% for patients with high-risk disease. The primary limitation of this and other prognostic models is that such guides were derived from patients who received alkylating agent-based therapy; therefore the utility of these models in the era of nucleoside analogs is unknown. Nevertheless, in other lymphoid malignancies where nucleoside analogs have been effective, prognostic factors for survival to alkylating agents have been similar for therapy with nucleoside analogs. 23,24 Thus, it is reasonable to explore high-dose chemotherapy in patients with WM who have poor risk features, particularly young patients with cytopenias and low albumin levels. However, until more experience is obtained, HDC and SCT for WM should only be explored in the context of well-designed clinical trials. (2) What stem cell source should be used when exploring HDC and SCT as consolidation therapy for patients with WM? Should we only try autologous SCT with HDC as consolidation treatment in newly diagnosed WM patients with poor prognostic features or should we also try allogeneic SCT when there is a donor available? Based on the limited current experience with HDC and SCT in WM only autografting should be explored as consolidation therapy for an initial remission in patients with WM. Experience to date in patients mostly with relapsing disease, has demonstrated that non-relapse mortality for autografting in WM is low ( 5%), and long-term remissions in relapsing or refractory patients can be achieved. The applicability and feasibility of autografting in patients with high-risk WM, is still unclear, since the feasibility of collecting enough stem cells, particularly after prior exposure to nucleoside analogs is as yet unknown. There are studies indicating that prior nucleoside analog exposure, negatively affects stem cell collection. 25,26 A recent retrospective study from Europe regarding mobilization of autologous peripheral blood SC in CLL patients with prior treatment with fludarabine, indicates that patients who had received fludarabine in combination with other chemotherapy regimens, or in patients who received the last dose of fludarabine within 2 months of stem cell collection, peripheral blood stem cell content was reduced, whereas administration of single agent fludarabine early in the disease course did not hamper successful collection. 27 The effect of cladribine on stem cell collection has also not been well explored, but potentially could also affect stem cell collections even with limited exposure. The use of allogeneic transplantation as a consolidation treatment in high-risk patients might become an issue in certain cases. However, existing data do not support the hypothesis that the potential benefits of a graft-versusmacroglobulinemia effect would overcome the risk of the severe adverse outcomes of GVHD or severe life-threatening infections, in patients having achieved remission of their disease. (3) Should high-dose chemotherapy and stem cell transplantation be explored as salvage therapy for Waldenstrom s macroglobulinemia? Response to first line treatment is a strong predictive factor for survival in WM, the median survival for patients not responding to therapy is less than 3.5 years. 3,4 Review of the published literature suggests that SCT can be used with success in WM and that this therapeutic option can be offered to patients relapsing or not responding to initial therapy. In this situation, HDC and SCT should preferentially be offered in the context of a clinical trial. The type of transplant will depend on the ability to collect autologous stem cells and the availability of an HLA compatible donor. However, the optimal cell source is unknown at this time. Although published experience suggests a graft-versus-wm effect, 11,14 this has not been documented in series of patients. The morbidity and mortality of allogeneic transplantation is always higher than autologous transplantation. Although non-ablative transplantation has been shown to reduce morbidity and mortality significantly in patients with low-grade lymphomas and other hematologic malignancies, this procedure does not eliminate the occurrence of acute or chronic GVHD that still impact tremendously on the quality of life post transplant At this time, based upon current results, if autologous stem cells can be collected autografting would be our favored approach in patients with primary refractory disease. If an adequate number of autologous stem cells cannot be collected, allografting is a reasonable alternative if an HLAcompatible donor is found. Data on allografting are still very limited and the risks outweigh the potential benefits of choosing an allogeneic transplant in refractory patients where autologous SCT is feasible. On the other hand, HDC alone has been shown to overcome disease resistance in WM patients (Table 1) and this should be our first choice in these cases. The majority of patients with WM will fall into the group of patients who respond to the first line therapy and relapse a few years later. Their chances of responding to salvage therapy are good. Prognostic factors for salvage therapy have not been developed, but are likely to parallel those for initial therapy and could be used to segregate patients into more or less aggressive treatment strategies. As with most lymphoid malignancies, response to salvage therapy has been shown to be an important prognostic factor for survival. Patients failing salvage therapy with 945
4 946 alkylators, have only a 21% chance of responding to nucleoside analogues, and a median survival of 13 months. 1 Review of the current transplant experience would suggest that these patients would be appropriate candidates for HDC and SCT in the context of a clinical trial as long as their performance status was adequate and they had an adequate source of stem cells. Transformation into a more aggressive histology although rare, has usually been associated with a poor outcome, and could also be considered as an appropriate indication to explore more aggressive therapy with SCT. For refractory disease patients, however, allografting may be the only treatment modality available, since autologous stem cells may not be available, and other therapy is unlikely to produce meaningful remissions. In low-grade lymphoma, patients with chemorefractory relapses had a substantial chance of long-term disease control after allografting, underscoring the relevance of the graft-versuslymphoma effect in this disease. 32,33 However, although classified as a low-grade lymphoid malignancy, neither the existence nor the relevance of a graft-versus- Waldenstrom s effect has been clearly demonstrated to date. Future prospects The fact that WM is a rare disease makes it difficult to perform prospective studies. Recent advances in other lymphoid malignancies like multiple myeloma or other low-grade lymphomas allows us to make new therapeutic approaches. The use of anti-cd20 and thalidomide are good examples. 7,8 The use of anti-cd20 in conjunction with HDC, or the use of thalidomide as maintenance post transplant might improve outcomes in WM patients. The optimal preparative regimen for patients undergoing autologous SCT has not yet been identified, nor is the intensity of the preparative regimen in the allogeneic SCT standard. However, using reduced intensity regimens in the allogeneic setting may induce donor cell engraftment with limited toxicities and may allow us to use this as a platform for further immune-mediated anti-macroglobulinemia effects. Consistent reporting and accumulation of sporadic WM cases treated with HDC, and participation of new cases in multi-institutional treatment protocols, might help us make advances in this area. Moreover, advances in the understanding of the molecular and genetic basis of the disease could also incorporate more intelligent diseasespecific treatments in the setting of SCT. Conclusion Waldenstrom s macroglobulinemia is a rare disease of elderly individuals. Historically, SCT is a treatment for younger patients without other medical conditions. Recent advances in supportive care, as well as the use of peripheral blood as a stem cell source has extended the use of SCT to patients with advanced ages and significant co-morbidities. The limited available data for SCT in WM patients should encourage investigators to prospectively study the role of HDC and SCT in WM. As with other indolent lymphoid malignancies, development of surrogate markers and endpoints will be essential to be able to better study the role and effects of HDC and SCT in patients with WM. References 1 Dimopoulos MA, Panayiotidis P, Moulopoulos LA et al. Waldenstrom s macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18: Gobbi PG, Bottini R, Montecucco C et al. Study of prognosis in Waldenstrom s macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood 1994; 83: Facon T, Brouillard M, Duhamel A et al. Prognostic factors in Waldenstrom s macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11: Dimopoulos MA, Alexanian R. Waldenstrom s macroglobulinemia. Blood 1994; 83: Dhodapkar MV, Jacobson JL, Gertz MA et al. Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003). Blood 2001; 98: Legouffe E, Rossi JF, Laporte JP et al. Treatment of Waldenstrom s macroglobulinemia with very low doses of alpha interferon. Leuk Lymphoma 1995; 19: Weide R, Heymanns J, Koppler H. Induction of complete haematological remission after monotherapy with anti-cd20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenstrom s macroglobulinaemia. Leuk Lymphoma 1999; 36: Dimopoulos MA, Zomas A, Viniou NA et al. Treatment of Waldenstrom s macroglobulinemia with thalidomide. J Clin Oncol 2001; 19: Desikan R, Dhodapkar M, Siegel D et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom s macroglobulinaemia. Br J Haematol 1999; 105: Dreger P, Glass B, Kuse R et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom s macroglobulinaemia. Br J Haematol 1999; 106: Anagnostopoulos A, Dimopoulos MA, Aleman A et al. Highdose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom s macroglobulinemia. Bone Marrow Transplant 2001; 27: Moustafa MPJ, Treleaven J, Horton C, Sirohi B. Total therapy with VAMP/CVAMP+ high dose melphalan and autograft for IgM lymphoplasmacytoid disease. Blood 1998; 92 (Suppl. 1) (Abstr. 4212). 13 Mazza P, Palazzo G, Amurri B et al. Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report. Bone Marrow Transplant 1999; 23: Ueda T, Hatanaka K, Kosugi S et al. Successful non-myeloablative allogeneic peripheral blood stem cell transplantation (PBSCT) for Waldenstrom s macroglobulinemia with severe pancytopenia. Bone Marrow Transplant 2001; 28: Yang L, Wen B, Li H et al. Autologous peripheral blood stem cell transplantation for Waldenstrom s macroglobulinemia. Bone Marrow Transplant 1999; 24: Martino R, Shah A, Romero P et al. Allogeneic bone marrow transplantation for advanced Waldenstrom s macroglobulinemia. Bone Marrow Transplant 1999; 23:
5 17 Dimopoulos MA, Kantarjian H, Weber D et al. Primary therapy of Waldenstrom s macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994; 12: Fridrik MA, Jager G, Baldinger C et al. First-line treatment of Waldenstrom s disease with cladribine. Ann Hematol 1997; 74: Dimopoulos MA, Weber D, Delasalle KB et al. Treatment of Waldenstrom s macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol 1995; 6: Delannoy A, van den Neste E, Michaux JL et al. Cladribine for Waldenstrom s macroglobulinaemia. Br J Haematol 1999; 104: Liu ES, Burian C, Miller WE, Saven A. Bolus administration of cladribine in the treatment of Waldenstrom macroglobulinaemia. Br J Haematol 1998; 103: Morel P, Monconduit M, Jacomy D et al. patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96: McLaughlin P, Robertson LE, Keating MJ. Fludarabine phosphate in lymphoma: an important new therapeutic agent. Cancer Treat Res 1996; 85: O Brien S, Kantarjian H, Beran M et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: Ketterer N, Salles G, Moullet I et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: Visani G, Lemoli RM, Tosi P et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol 1999; 105: Michallet M, Thiebaut A, Dreger P. Peripheral blood stem cell (PBSC) mobilization and transplantation after fludarabine therapy in chronic lymphocytic leukaemia (CLL): a report of the European Blood and Marrow Transplantation (EBMT) CLL subcommittee on behalf of the EBMT Chronic Leukaemias Working Party (CLWP). Br J Haematol 2000; 108: Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitorcell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus- tumor effects. Blood 2001; 97: Slavin S, Or R, Aker M, Shapira MY et al. Nonmyeloablative stem cell transplantation for the treatment of cancer and lifethreatening nonmalignant disorders: past accomplishments and future goals. Cancer Chemother Pharmacol 2001; 48 (Suppl. 1): S van Besien KW, Mehra R, Giralt SA et al. Allogeneic bone marrow transplantation for poor prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 1996; 100: Khouri I, Lee MS, Palmer L et al. Transplant-lite using fludarabine cyclophosphamide and allogeneic stem cell transplant for low grade lymphoma. Blood 1999; 94 (Suppl. 1): 348a. 947
Treatment for Waldenstrom s macroglobulinemia
Review Annals of Oncology 15: 550 558, 2004 DOI: 10.1093/annonc/mdh128 Treatment for Waldenstrom s macroglobulinemia C. I. Chen* Princess Margaret Hospital/Ontario Cancer Institute, Toronto, Ontario, Canada
More informationTreatment for Waldenstrom s macroglobulinemia
Review Annals of Oncology 15: 550 558, 2004 DOI: 10.1093/annonc/mdh128 Treatment for Waldenstrom s macroglobulinemia C. I. Chen* Princess Margaret Hospital/Ontario Cancer Institute, Toronto, Ontario, Canada
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for Waldenstrom Macroglobulinemia File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem_cell_transplantation_for_waldenstrom_macroglobulinemia
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationSurvival and prognostic factors after initiation of treatment in Waldenstrom s macroglobulinemia
Original article Annals of Oncology 14: 1299 1305, 2003 DOI: 10.1093/annonc/mdg334 Survival and prognostic factors after initiation of treatment in Waldenstrom s macroglobulinemia M. A. Dimopoulos*, G.
More informationA.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)
chapter 4 The significance of monoclonal plasma cells in the bone marrow biopsies of patients with multiple myeloma following allogeneic or autologous stem cell transplantation A.M.W. van Marion H.M. Lokhorst
More informationWALDENSTROM S macroglobulinemia (WM) is a
Treatment of Waldenstrom s Macroglobulinemia With Thalidomide By Meletios A. Dimopoulos, Athanassios Zomas, Nora A. Viniou, Vassiliki Grigoraki, Eleni Galani, Charis Matsouka, Olga Economou, Nikolaos Anagnostopoulos,
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationTraditional Therapies for Waldenstrom s Macroglobulinemia. Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014
Traditional Therapies for Waldenstrom s Macroglobulinemia Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014 Jeff Atlin (1953-2014) Standard treatment options Single drug therapies
More informationDIAGNOSIS AND TREATMENT OF WALDENSTRÖM S MACROGLOBULINAEMIA IN THE NETHERLANDS. Monique Minnema UMC Utrecht
DIAGNOSIS AND TREATMENT OF WALDENSTRÖM S MACROGLOBULINAEMIA IN THE NETHERLANDS Monique Minnema UMC Utrecht Organisation of hematological care in the Netherlands Intensive chemotherapy, including acute
More informationguidelines British Committee for Standards in Haematology Waldenström s macroglobulinaemia Guidelines on diagnosis and therapy
British Society for Haematology British Committee for Standards in Haematology Guidelines on diagnosis and therapy guidelines Abbreviations ALL ALT AML BM CAP 2-CDA CHOP CLL CML COP CR CT CVP 2 -DCF DFI
More informationWaldenström Macroglobulinemia Irene M. Ghobrial, MD Thomas E. Witzig, MD *
Waldenström Macroglobulinemia Irene M. Ghobrial, MD Thomas E. Witzig, MD * Address * Division of Hematology, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA. E-mail: witzig.thomas@mayo.edu Current
More informationHematopoietic Cell Transplantation for Primary Amyloidosis or Waldenstrom s Macroglobulinemia
Hematopoietic Cell Transplantation for Primary Amyloidosis or Waldenstrom s Macroglobulinemia Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More informationUPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma
UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Supported by a grant from Supported by a grant from UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma Jonathan W.
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationDiagnosis and Management of Waldenstrom s Macroglobulinemia Meletios A. Dimopoulos, Robert A. Kyle, Athanasios Anagnostopoulos, and Steven P.
VOLUME 23 NUMBER 7 MARCH 1 2005 JOURNAL OF CLINICAL ONCOLOGY R E V I E W A R T I C L E Diagnosis and Management of Waldenstrom s Macroglobulinemia Meletios A. Dimopoulos, Robert A. Kyle, Athanasios Anagnostopoulos,
More informationDr Claire Burney, Lymphoma Clinical Fellow, Bristol Haematology and Oncology Centre, UK
EMBT LWP 2017-R-05 Research Protocol: Outcomes of patients treated with Ibrutinib post autologous stem cell transplant for mantle cell lymphoma. A retrospective analysis of the LWP-EBMT registry. Principle
More informationDivision of Hematology, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
The Oncologist Fundamentals of Cancer Medicine Waldenström s Macroglobulinemia MORIE A. GERTZ, RAFAEL FONSECA, S. VINCENT RAJKUMAR Division of Hematology, Department of Internal Medicine, Mayo Clinic and
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_ transplantation_for_primary_amyloidosis 2/2001 11/2018 11/2019 11/2018 Description
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationResearch Article Wiley Periodicals, Inc.
Research Article Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005 Sigurdur Y. Kristinsson,
More informationTransplantation in Chronic Lymphocytic Leukemia: Timing and Expectations
CLL Leukemia 2008 Proceedings Transplantation in Chronic Lymphocytic Leukemia: Timing and Expectations Simon Hallam, John G. Gribben Abstract Stem cell transplantation in chronic lymphocytic leukemia (CLL)
More informationTreatment of Waldenström s Macroglobulinemia Mayo Consensus
Treatment of Waldenström s Macroglobulinemia Mayo Consensus Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo Clinic Comprehensive Cancer Center Mayo Clinic
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationPrognostic markers and criteria to initiate therapy in Waldenstrom s Macroglobulinemia
Prognostic markers and criteria to initiate therapy in Waldenstrom s Macroglobulinemia Consensus Panel Recommendations from the Second International Workshop on Waldenstrom s Macroglobulinemia Robert A.
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_cell_transplantation_for_cll_and_sll 2/2001
More informationDr.PSRK.Sastry MD, ECMO
Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical
More informationNon-Myeloablative Transplantation
Non-Myeloablative Transplantation David G. Maloney, Brenda M. Sandmaier, Stephen Mackinnon, and Judith A. Shizuru The concept of utilizing enhanced immunosuppression rather than myeloablative cytotoxic
More informationRituximab, and autologous stem cell collection rate after induction therapy with Bortezomib-Rituximab. 4 Not yet recruiting
1 Recruiting A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Conditions: Waldenstrom's ; Waldenstrom Macroglobulinaemia Intervention: Biological: Ofatumumab Sponsor: GlaxoSmithKline Number
More informationAppendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand
Appendix 6: Indications for adult allogeneic bone marrow transplant in New Zealand This list provides indications for the majority of adult BMTs that are performed in New Zealand. A small number of BMTs
More informationWaldenstrom s Macroglobulinemia
Waldenstrom s Macroglobulinemia : Introduction Waldenstrom s macroglobulinemia (WM) is a lymphoma, or cancer of the lymphatic system. It occurs in a type of white blood cell called a B-lymphocyte or B-cell,
More informationHematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome
Hematopoietic Stem-Cell Transplantation for Plasma Cell Dyscrasias, Including Multiple Myeloma and POEMS Syndrome Policy Number: 8.01.17 Last Review: 2/2018 Origination: 12/2001 Next Review: 2/2019 Policy
More informationComparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin s Lymphoma
Biology of Blood and Marrow Transplantation 12:1326-1334 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1212-0001$32.00/0 doi:10.1016/j.bbmt.2006.08.035 Comparison of Reduced-Intensity
More informationReduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation for LLM: Hype, Reality or Time for a Rethink
Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation for LLM: Hype, Reality or Time for a Rethink Avichi Shimoni, Arnon Nagler Hematology Division and BMT, Chaim Sheba Medical Center,
More informationEBMT2008_22_44:EBMT :29 Pagina 454 CHAPTER 30. HSCT for Hodgkin s lymphoma in adults. A. Sureda
EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 454 * CHAPTER 30 HSCT for Hodgkin s lymphoma in adults A. Sureda EBMT2008_22_44:EBMT2008 6-11-2008 9:29 Pagina 455 CHAPTER 30 HL in adults 1. Introduction
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More informationReduced intensity conditioning regimens
Reduced intensity conditioning regimens (2002) 30, 63 68 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Low transplant-related mortality after second allogeneic
More informationMedical Benefit Effective Date: 07/01/12 Next Review Date: 03/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 03/10, 03/11, 03/12
Hematopoietic Stem-Cell Transplantation for Chronic Myelogenous (80130) Medical Benefit Effective Date: 07/01/12 Next Review Date: 03/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 03/10, 03/11,
More informationMedical Benefit Effective Date: 07/01/12 Next Review Date: 05/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 05/11, 05/12
Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic (80115) Medical Benefit Effective Date: 07/01/12 Next Review Date: 05/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 05/11, 05/12 The
More informationManaging Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options
Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options Fernando Cabanillas (Chair), Sandra Horning, Mark Kaminski, and Richard Champlin The front-line management of stage
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationAIH, Marseille 30/09/06
ALLOGENEIC STEM CELL TRANSPLANTATION FOR MYELOID MALIGNANCIES Transplant and Cellular Therapy Unit Institut Paoli Calmettes Inserm U599 Université de la Méditerranée ée Marseille, France AIH, Marseille
More informationPediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center
Pediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology
More informationKEY WORDS: CRp, Platelet recovery, AML, MDS, Transplant
Platelet Recovery Before Allogeneic Stem Cell Transplantation Predicts Posttransplantation Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome Gheath Alatrash, Matteo Pelosini,
More informationProtocol. Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis
Protocol Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis (80142) Medical Benefit Effective Date: 04/01/13 Next Review Date: 07/15 Preauthorization Yes Review Dates: 04/07, 05/08, 01/10,
More informationReference: NHS England 1602
Clinical Commissioning Policy Proposition: Clofarabine for refractory or relapsed acute myeloid leukaemia (AML) as a bridge to stem cell transplantation Reference: NHS England 1602 First published: TBC
More informationAML:Transplant or ChemoTherapy?
AML:Transplant or ChemoTherapy? 1960 s: Importance of HLA type in Animal Models Survival of Dogs Given 1000 RAD TBI and a Marrow Infusion from a Littermate Matched or Mismatched for Dog Leucocyte Antigens
More informationKR Desikan, G Tricot, M Dhodapkar, A Fassas, D Siegel, DH Vesole, S Jagannath, S Singhal, J Mehta, D Spoon, E Anaissie, B Barlogie and N Munshi
(2000) 25, 483 487 2000 Macmillan Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nature.com/bmt Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning
More informationSTEM-CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
STEM-CELL TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA Carol Moreno Department of Hematology, Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain Introduction
More informationAllogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström s macroglobulinemia.
Original Articles Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström s macroglobulinemia. Results of a retrospective analysis
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationNational Horizon Scanning Centre. Rituximab (MabThera) for chronic lymphocytic leukaemia. September 2007
Rituximab (MabThera) for chronic lymphocytic leukaemia This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationTHE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore
THE ROLE OF TBI IN STEM CELL TRANSPLANTATION Dr. Biju George Professor Department of Haematology CMC Vellore Introduction Radiotherapy is the medical use of ionising radiation. TBI or Total Body Irradiation
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationSecond Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival
Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival Victor H. Jimenez-Zepeda, 1 Joseph Mikhael, 2 Andrew Winter, 1 Norman
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationHigh-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma
Biology of Blood and Marrow Transplantation 12:703-711 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1207-0002$32.00/0 doi:10.1016/j.bbmt.2006.02.009 High-Dose Carmustine,
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationMedical Policy Title: HDC Progenitor Cell ARBenefits Approval: 02/08/2012
Medical Policy Title: HDC Progenitor Cell ARBenefits Approval: 02/08/2012 Support AL Amyloidosis (Light Chain Amyloidosis) Effective Date: 01/01/2013 Document: ARB0413:01 Revision Date: 10/24/2012 Code(s):
More informationArsenic Trioxide: An Emerging Therapy for Multiple Myeloma
Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma NIKHIL C. MUNSHI University of Arkansas for Medical Science, Little Rock, Arkansas, USA Key Words. Arsenic trioxide Multiple myeloma Antiangiogenesis
More informationHCT for Myelofibrosis
Allogeneic HSCT for MDS and Myelofibrosis Sunil Abhyankar, MD Professor Medicine, Medical Director, Pheresis and Cell Processing University of Kansas Hospital BMT Program April 27 th, 213 HCT for Myelofibrosis
More informationReduced intensity conditioning for allogeneic haematopoietic stem cell transplantation (HSCT)
1 Reduced intensity conditioning for allogeneic haematopoietic stem cell transplantation (HSCT) S. Servais, Y. Beguin, F. Baron Reduced intensity conditioning (RIC) regimens have allowed performing allogeneic
More informationHematology 101. Rachid Baz, M.D. 5/16/2014
Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationThe Map of Current Treatment Options for Waldenström Macroglobulinemia
The Map of Current Treatment Options for Waldenström Macroglobulinemia Craig Reeder Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida DISCLOSURES Relevant Financial Relationship(s)
More informationModule 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning
Module 3: Multiple Myeloma Induction and Transplant Strategies Treatment Planning Challenge Question: Role of Autologous Stem Cell Transplant Which of the following is true about eligibility for high-dose
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationMyeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris
Myeloablative and Reduced Intensity Conditioning for HSCT Annalisa Ruggeri, MD, Hôpital Saint Antoine Eurocord- Hôpital Saint Louis, Paris 18th ESH - EBMT Training Course on HSCT 8-10 May 2014, Vienna,
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationSTEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA
STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan.
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More informationNonmyeloablative Allogeneic Transplants of Hematopoietic Stem Cells for Treatment of Malignancy Archived Medical Policy
Nonmyeloablative Allogeneic Transplants of Hematopoietic Stem Cells for Treatment of Malignancy Codes associated with this policy will no longer pend for clinical review. Applies to all products administered
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 ARZERRA 100 mg, concentrate for solution for infusion B/3 (CIP code: 577 117-9) B/10 (CIP code: 577
More informationRelapse After Transplant: Next Steps for Patients with Hodgkin Lymphoma
Hi! My name is Alison Moskowitz. I am an attending at Memorial Sloan Kettering Cancer Center within the Lymphoma Department. I am speaking on behalf of ManagingHodgkinLymphoma.com. I will be discussing
More informationProceedings of the World Small Animal Veterinary Association Sydney, Australia 2007
Proceedings of the World Small Animal Sydney, Australia 2007 Hosted by: Next WSAVA Congress WHAT IS THE BEST PROTOCOL FOR CANINE LYMPHOMA? Antony S. Moore, M.V.Sc., Dipl. A.C.V.I.M. (Oncology) Veterinary
More informationTransition from active to palliative care EBMT, Geneva, Dr. med. Gayathri Nair Division of Hematology
Transition from active to palliative care EBMT, Geneva, 03.04.2012 Dr. med. Gayathri Nair Division of Hematology 3 cases of patients who underwent an allogeneic stem cell transplantation in curative intent
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplant for Non-Hodgkin Lymphomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplant_for_non_hodgkin_lymphomas
More informationNational Horizon Scanning Centre. Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory. January 2008
Temsirolimus (Torisel) for mantle cell lymphoma - relapsed and/or refractory January 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationBendamustine for relapsed follicular lymphoma refractory to rituximab
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationClinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
More information37 Novel Therapies for
37 Novel Therapies for Multiple Myeloma Abstract: Current standard of management for newly diagnosed multiple myeloma are continuously evolving due to the advent of a number of novel agents with different
More informationM Cavo, G Bandini, M Benni, A Gozzetti, S Ronconi, G Rosti, E Zamagni, RM Lemoli, A Bonini, A Belardinelli, MR Motta, S Rizzi and S Tura
Bone Marrow Transplantation, (1998) 22, 27 32 1998 Stockton Press All rights reserved 268 3369/98 $12. http://www.stockton-press.co.uk/bmt High-dose busulfan and cyclophosphamide are an effective conditioning
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationI Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015
I Need Treatment First-Line WM Treatments & Side Effects IWMF Educational Forum Grapevine, TX 5/1/2015 Larry Anderson, MD, PhD Plasma Cell Disorder and Stem Cell Transplant Specialist UT Southwestern Medical
More informationBB&MT. KEY WORDS Reduced-intensity regimen Allogeneic hematopoietic stem cell transplantation
Biology of Blood and Marrow Transplantation 9:189 197 (2003) 2003 American Society for Blood and Marrow Transplantation 1083-8791/03/0903-0007$30.00/0 doi: 10.1053/bbmt.2003.50012 Lowered-Intensity Preparative
More informationHematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia Policy Number: 8.01.32 Last Review: 7/2018 Origination: 7/2002 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationHematopoietic Cell Transplantation for Epithelial Ovarian Cancer
Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer Policy Number: 8.01.23 Last Review: 1/2018 Origination: 9/2002 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationLymphomas and multiple myeloma 12/23/2018 1
60 Lymphomas and multiple myeloma 12/23/2018 1 Lymphomas Lymphoma is cancer of the lymphatic system. Lymphomas are subdivided into two main categories: Hodgkin's lymphoma (HL) and non- Hodgkin's lymphoma
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More information